摘要
目的:探讨前列腺特异性抗原(PSA)测定在有下尿路症状的良性前列腺增生(BPH)患者的临床意义。方法:比较520例有症状和196例无症状的BPH患者的总PSA(tPSA),游离PSA(fPSA)和fPSA/tPSA等指标,并进行统计学分析。结果:有症状组和无症状组的tPSA值分别为(5.13±2.49)、(1.73±1.26)μg/L,差异有极显著性(P<0.01);fPSA分别为(1.57±0.80)、(0.54±0.38)μg/L,差异有极显著性(P<0.01);fPSA/tPSA分别为0.31±0.09和0.30±0.11,差异无显著性(P>0.05)。结论:有下尿路症状BPH患者的tPSA、fPSA明显高于无症状,但fPSA/tPSA比值在BPH患者中稳定。
Objective: To evaluate the clinical significance of prostatic-specific antigen (PSA) levels in patients with benign prostatic hyperplasia (BPH) complicated by low urinary tract syndrome(LUTS). Methods. The levels of tPSA, tTSA and tTSA/tPSA ratio were detected and compared in 520 cases of BPH with LUTS and 196 cases without LUTS. Results : The mean levels of tPSA in the cases of BPH with LUTS and without LUTS were ( 5.13±2.49 )μg/L and ( 1.73 ±1.26)μg/L respectively ( P 〈 0.01 ). The mean levels fPSA were ( 1.57 ±0.80) μg/L and (0.54±0.38 )μg/L respectively( P 〈 0.01 ). The mean ratios of fPSA/tPSA were (0.31±0.09 ) and ( 0.30±0.11 ) respectively ( P 〉 0.05 ). Conclusion : The levels of tPSA, fPSA are significantly higher in the cases of BPH with LUTS than those in the cases without LUTS, but the ratio of fPSA/tPSA is stable in BPH.
出处
《中华男科学杂志》
CAS
CSCD
2006年第2期156-158,共3页
National Journal of Andrology
关键词
良性前列腺增生
下尿路症状
前列腺特异性抗原
benign prostatic hyperplasia
lower urinary tract syndrome
prostatic specific antigen